子宫内膜癌的分子检测:SGO临床实践声明
该实践声明旨在指导子宫内膜癌分子检测的合理应用、解读与临床实践。所有子宫内膜癌均应进行基本分子分型,包括错配修复状态评估;POLE与p53状态具有预后价值,未来可能成为可干预靶点。临床医生应理解分子分型在指导治疗中的作用。
要点
- 所有子宫内膜癌均应进行基本分子分型,包括错配修复状态评估。
- POLE与p53状态具有预后价值,未来可能成为可干预靶点。
- 临床医生应理解分子分型在指导子宫内膜癌治疗中的作用。
核心结论
- 所有子宫内膜癌均应进行基本分子分型,包括错配修复状态评估;POLE与p53状态具有预后价值,未来可能成为可干预靶点;临床医生应理解分子分型在指导治疗中的作用。
研究设计与样本
- 该文件为SGO临床实践声明,旨在指导子宫内膜癌分子检测的合理应用、解读与临床实践。
主要发现
- 癌症基因组图谱首次描述了子宫内膜癌的基因组景观,并将其分为四种预后不同的分子亚型。
- proactive分子分类器被开发用于更简便、低成本地将子宫内膜癌分为POLE、错配修复缺陷、p53异常和无特定分子谱四种相似分子亚型。
- 除四种亚型外,其他分子生物标志物可能影响临床行为及靶向治疗反应,包括β-catenin、Her2扩增、PI3K/mTOR/AKT改变、L1CAM、激素受体表达、肿瘤突变负荷和ARID1A。
- 多项临床试验正在探索四种分子亚型内的治疗升级与降级,以及将靶向治疗与特定突变或生物标志物谱匹配。
关键数值与推荐
- 所有子宫内膜癌均应进行基本分子分型,包括错配修复状态评估。
- POLE与p53状态具有预后价值,未来可能成为可干预靶点。
- 临床医生应理解分子分型在指导子宫内膜癌治疗中的作用。
临床怎么用
- 临床医生应理解分子分型在指导子宫内膜癌治疗中的作用,并对所有子宫内膜癌进行基本分子分型,包括错配修复状态评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Cancer Genome Atlas publication first described the genomic landscape of endometrial cancer and characterized these cancers into four molecular subtypes with different prognoses. The Proactive Molecular Classifier for Endometrial Cancer was developed to more easily and inexpensively classify endometrial cancers into four similar molecular subtypes which are termed POLE, mismatch repair deficient, p53 abnormal and no specific molecular profile. Beyond these four subtypes, other molecular biomarkers may influence clinical behavior and response to targeted therapies and include beta-catenin, Her2 amplification, PI3K/mTOR/AKT alterations, L1CAM, hormone receptor expression, tumor mutational burden, and ARID1A. There are numerous clinical trials exploring treatment escalation and de-escalation within the four molecular subtypes as well as matching targeted therapies to specific mutational or biomarker profiles. All endometrial cancers should undergo basic molecular classification that includes assessment of mismatch repair status. POLE and p53 status are prognostic and may become actionable in the future. Clinicians who treat patients with endometrial cancer should understand the role of molecular classification in guiding treatment. The goal of this practice statement is to guide appropriate testing, interpretation, and application of molecular information in endometrial cancer.
引用
- Walsh CS, Hacker KE, Secord AA, et al. Molecular testing for endometrial cancer: An SGO clinical practice statement. Gynecol Oncol. 2022. PMID: 36399812. doi:10.1016/j.ygyno.2022.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。